My daughter is an artist and a bit of a photographer. I think she took pictures of San Fruttuosa, too! It looks gorgeous. I'd eat there. Frankly, I'd eat anywhere in Italy!! It's all good.
Well, we allow you to post on the mb. This is a free country.
I love Camogli! My daughter took a photo of the beach with the Chiesa at the end. It turned out fantastic so we had it enlarged and had a process done to it and it hangs in our home. I love looking at it. Can we eat in one of those Cafe's overlooking the beach?
After Gerald made his presentation in Santa Monica...those who wanted to talk with him were ushered into another room with a lot of tables set up, not for eating, but for people to talk. My son and I sat with Gerald, Robert Ferrell (the new Financial Guy) and Dan Boucher. (He works with Investor Relation, husband to Aimee) We spoke for about 30 minutes. I can see where you might have though we had dinner together. But, if I were to eat with you in Genova, I should require Gnocchi al Pesto, un panino, e un po di gelato. E basta! LOL.
In Copenhagen Poster 1 was Beckton Dickenson's validation of the science of two LymPro tests performed by Steiller back in 2001 and 2012. Those spec & sens numbers were 90 & 95%. What was nice about this is that BD was able to validate that the science of LymPro was sound. This got the attention of the AD scientific community. But we shareholders were disappointed because Gerald didn't give the BD test data that has been done in 2014. Why didn't he? 2.5 months ago when my son and I spoke with Gerald in Santa Monica he told us of a "larger test" BD would do (140, 160, to 200 patient) as part of the "Analytical Performance....thing" He indicated to us that those numbers would be available by July. So then why didn't we get them? Well, I don't think they did that "larger test." I think when they bought version 2 of LymPro it changed their plans. Instead of doing the "larger test," they decided to do the "bridge test" comparing version 1 to version 2. (A 72 patient test) That "top line" data will be presented on the 31st. In Gerald's blog last week he said once we get into our CLIA partner's lab we will do a "larger test" to validate LymPro in that partner's lab prior to commercializing., So in a nutshell, acquiring version 2 changed the timing of some of their tests but in the end, it will only improve results. I believe on the 31st we'll get the "raw meat" LymPro data the market has been waiting for, and I believe Gerald's methodical approach will mean we'll have the scientific community with us, rather than poking holes in LymPro's science. The diagnostic experts Gerald has brought on wouldn't have come unless LymPro was the real deal. I wish Gerald had communicated better, but nevertheless, I believe we are in a great position right now. My concerns have been resolved. Load up!!
You're infinitely dumb! You don't understand what was presented in the posters in the least! You're a soft basher, pure and simple. The truth is LymPro is in great shape and the numbers revealed on the 31st will confirm that. The science is what was confirmed in Copenhagen. Stop trying to mislead people with your ignorance.
The way you have to look at things is that if we dropped below .10 cents because the data was not as great as Gerald has indicated it is....that would hurt AMBS even more than it would hurt you! Gerald has really expanded based on his belief he has the goods to raise the pps, up list, and become a world class company. If the data sucked, Gerald would be ruined. That isn't going to happen. I've done enough dd that I am able to sleep nights. You have to do your own dd to have the conviction to take risks with this stock. If I had money I would buy as many shares at .13 to .14 cents as I could. But that's just me.
Yes, the data will be compelling! Your .175 cent purchases will not be a problem for you, especially if you can buy some tomorrow in the .13 cent range.
Last Tuesday morning as the market opened, we gapped up above .16 cents from the .156 cent close on Monday. We experienced a firestorm in the first 15 minutes of trading with the pps hitting .175 cents on about 15 million shares traded!! If the news everyone was expecting regarding LymPro's data had come out and the sens and spec numbers done by BD this year were in the mid 90ies range....the pps would have exploded well above .20 cents. I think it might have hit .25 cents or even higher for an intra day high. It would have gone back down and tested .20 cents or maybe dipped below it to .19 or .18 cents for a bit. But I believe the close would have been above .20 cents on Tuesday. But Gerald delayed the data and we all know what happened. I don't think Gerald will withhold that data on the 31st. Too much is on the line! He will release the data and we will resume our march above .20 cents. But, Gerald may have extra fuel to add to the fire on the 31st regarding LymPro and TBI. Also, Cavendish will be co-sponsoring the Conference and they might provide some extra firepower in terms of their people investing in AMBS or giving grants to us. In any event, I believe by August 5th we'll be trading in the .20 to .25 cent range and will be talking about the "revenue guidance" Gerald said he would be giving us. That will be the next big catalyst that will move us well above .30 cents. After that, we have the LymPro partnership announcement toward the end of August which could take us well above .40 or .50 cents. We've got to remember that someone has been buying up a lot of the remaining float over the last couple of months. As these big catalysts hit there will be huge volume with lots of people trying to take a position with AMBS and #$%$ up those hard to get remaining shares. Lincoln Park Capital has a history of creating "squeezes" with companies they invest in and which have big news to announce. (Elite Pharma) If MANF joins the catalyst parade, watch out!!!!
Jegfsu: Gerald told me personally in Santa Monica 2.5 months ago that they would be doing a larger 140 to 160 man test with BD in the Q2. Then, after they got into the CLIA partner's lab, they would do another "small test" to get validated there. Because he told me that I was disappointed to not hear those results at Copenhagen. But I think what happened is they didn't do that "large test" in Q2. I think once they bought LymPro version 2 they changed plans. Instead of doing the "big test" they decided to do a "bridge test" comparing version 2 with version 1 which they will announce on July 31st. In Gerald's blog Thursday he said they will do a "larger test" once they are in their CLIA partner's lab. I think they did some switching around and that is why they didn't announce what I expected them to announce. But it is all good. Version 2 is probably a COMPETITION SLAYER!! I'm feeling better once I figured out some of the confusion.
I'll tell you why Gerald is going to release version 2 LymPro results July 31st and will give strong Revenue Guidance not long after that: he needs to get them out in order to help him drive a better deal with our LymPro partner! The stronger LymPro looks the more up front cash Gerald can demand. I think that will happen in August rather than the official end of summer. (Cannoli: thanks for your comments. I really do get beat up a lot!! (Yesterday I got ran out of town on Investorswarp, I mean Investorshangout. In the big shoot out, I think I lost half my behind!! LOL)
cannoli: No question our pps will be spiking up and down for the next few months! But the highs get higher, and the lows get higher too as we climb upward. For example, this weekend we all feel .135 is kind of sucky compared to the .175 intra day high we had Tuesday. We didn't fall below .10 cents after Copenhagen or .12 cents. I think our pps gradually moves up in anticipation of the LymPro data announcement on the 31st. On the heels of that announcement comes the Revenue Guidance and the LymPro Partnership, with some MANF data thrown in for good measure. So I don't see us staying below .20 cents after the .31st. Maybe we dip down below and maybe even close once or twice in the high teens after the 31st, but we will be moving upward in expectation of Revenue Guidance.
bballgm: Gerald is scheduled to speak in the afternoon which is probably when he will release the version 2 data. If he speaks around 3 pm, and the Conference isn't behind schedule, there will still be close to an hour that the market will be open to respond to those numbers. I sure hope they keep the Conference on schedule because I think we could see a fire storm in the final 30 minutes of trading on the 31st! Then over night more people will become alerted and we'll have an even bigger run up on Friday August 1st!
Buy the shares soon because I think the pps will drift up as we near the Conference. This last Tuesday morning the pps opened above .16 cents and raced up to .175 cents before the deflating delay in news was announced. So I would expect the pps to be somewhere in that range the morning of the 31st. Buy shares on Monday and when she asks you about it, say you bought her a present that won't arrive here until August 5th. Tell her if she doesn't like it she can return it and get a full refund. On August 1st, Friday, the stock will probably peak well above .20 cents, a handsome gain. Ask her what you should do? She'll probably tell you to sell enough to get your purchase price back and keep the rest. Explain what is happening with the stock in August and the coming months and see if she'll join your enthusiasm. If not you'll have to honor her request. But just look at how smart you'll look when you show her AMBS' pps in September, and beyond. She'll regret having disagreed with you. Trust me pal, that is worth it's weight in gold in a marriage, maybe even more than leaving the extra shares in AMBS. I'll send you my marriage counseling bill;-)
fpolma: Excellent, thanks for pointing that out. 4 guys dividing up one hour, 15 minutes each! It looks like Gerald "doesn't mind if he does" talk about LymPro at a Conference he's hosting!! Excellent!! And here is another speculation: Adam Simons is also on our Board of Scientific Advisers. He also owns a company with a "scanner" that detects" TBI & Alzheimers. Gerald has hinted at AMBS buying other assets, so has DocStock (who has disappeared). Wouldn't it be interesting if AMBS purchased Simon's company "Cerora?" With a Scanner and a Blood Test that would make them a pretty deadly duo for our competitors.Excellent!
zarc: I actually thought the same thing. As I was thinking about this post I wondered if the major reason Gerald started "Hosting" these Conferences was so that he could one day cash in on his credibility and use the Conference for maybe 15 minutes to splash the news about LymPro's break through data! It may seem self serving, but...
bankerman: It has been suggested that the #C4CT was a better forum than Copenhagen for us to release the big LymPro data. But, unless we actually have LymPro take center stage during the Conference proceedings...how is C4CT all that helpful to the LymPro data release? So, I am split as to whether Gerald will be able to actually talk about LymPro during the Conference. It might seem like high-jacking, but LymPro's data is a huge break through. I would be disappointed if the new LymPro data isn't highlighted DURING the Conference Proceedings.
At the last Concussion Summit in January I kept waiting for the focus of the Summit to be on AMBS but it never was. Gerald was co-hosting it, which was nice, but the subject matter discussed involved industry wide issues, and it might have been inappropriate for the "Co Host" to then high-jack the Conference and turn everyone's attention on AMBS' specific products....I guess it would have seemed self-serving for a Co-Host to do that. So I eventually stopped listening to the Conference because frankly, most of what was being discussed did not directly interest me. But that is what a Summit is for, to bring together experts and discuss big general issues that effect the entire industry. That is why I have had a hard time wondering how the actual #C4CT Conference proceedings could possibly be an appropriate forum for AMBS to trumpet LymPro data? I can't imagine very much of the Conference will focus on LymPro? What will probably happen is that AMBS will release the LymPro data in a PR around the time of the Conference so that Gerald can have something fun to speak about with important people in the hallways during Conference breaks.(Insert laughter here) But unless Gerald gets a prominent segment during the Conference for him to turn the entire Conference spotlight on LymPro's break through data, then waiting for #C4CT is not going to help us much. If LymPro does get that spot light during the Conference...then Gerald could smack the ball out of the United Nations Building!!! I hope our "Co-Hosting" duties don't get in the way of allowing that to happen. I've seen the Conference Agenda and there is an hour in the afternoon for Break Through issues. I've got my fingers crossed LymPro will be prominently featured during that hour.